Phase III data on BAX 111 (recombinant von Willebrand Factor) published in Blood- Baxalta
Baxalta Inc announced the publication of pivotal phase III data for BAX 111 (recombinant von Willebrand Factor) in Blood, the journal of the American Society of Hematology. The data showed that 100 percent of the patients treated with BAX 111, a highly purified recombinant von Willebrand factor (rVWF) candidate, achieved success in the management of bleeding episodes. BAX 111 is currently under review by the FDA. If approved, BAX 111 would become the first recombinant replacement treatment for managing bleeding episodes for von Willebrand patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins